ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0674

AKI Perspectives and Practices in Latin America (LA) During COVID-19: Analysis from GlomCon Latin America Working Group

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Soto-Vargas, Javier, Especialidad de Nefrología, Hospital General Regional 46, Guadalajara, Mexico
  • Garcia Anton, Desiree, University of Mississippi Medical Center, Jackson, Mississippi, United States
  • Aguirre, Diana, Hospital General de Mexicali, Mexicali, Mexico
  • Arellano-Mendez, Denisse, Unidad Medica de Atencion Ambulatoria 254, IMSS, Morelia, Mexico
  • Cabeza Rivera, Franco H., University of Mississippi Medical Center, Jackson, Mississippi, United States
  • Gutierrez-Prieto, Julio Alejandro, Hospital Central del Estado de Chihuahua, Chihuahua, Mexico
  • Martinez-Chagolla, Blanca, Hospital General “Dr. Miguel Silva”, Morelia, Mexico
  • Rodriguez Ramirez, Sonia, Multi-Organ Transplant Program, University Health Network, Toronto, Ontario, Canada
  • Avila-Casado, Carmen, Pathology Department, University Health Network, Toronto, Ontario, Canada

Group or Team Name

  • GlomCon Latin America Working Group

The epidemiology, clinical presentation, management and outcomes of COVID-19 comes from early reports from China and Europe with AKI prevalence ranging widely from 0.5% to 29%. However, knowledge about this pandemic is still emerging. With the epicenter now in the western hemisphere, we aim to determine the behavior and possible differences in presentation of AKI in COVID-19 patients in Latin America. To our knowledge, this is the first of such study.


Descriptive analysis extracted from an online survey carried out among nephrologists, renal pathologists and other health workers treating kidney diseases between May 20-27, 2020 from sixteen Spanish speaking Latin American countries divided into 6 categories. We present the results for the AKI category.


430 responses were obtained of which 360 (84%) were considered for analysis. 86% of the participants were nephrologists. 35% of the respondents reported the prevalence of AKI to be <5%, while 32% estimated it at 6-10%. The majority of AKI in these patients was stage 3 according to 31% of the respondents. Roughly half of the nephrologists witnessed new onset proteinuria which was almost exclusively (96%) sub-nephrotic. The majority (64%) reported no hematuria. Half of the participants (50.2%) reported that renal replacement therapy (RRT) was never or rarely required. Intermittent hemodialysis was the main RRT used reported by 88% of those surveyed followed by continuous renal replacement therapy (33%), peritoneal dialysis (24%) and prolonged intermittent RRT (19%). The most common complications during RRT were hypotension (60.3%) and circuit clotting (36.6%). Over one third of the participants (35%) estimated the mortality of patients with AKI and COVID to be <20%.


Our survey highlights potential differences in the presentation, management and outcomes of AKI in patients with COVID-19 in LA; among those, a lower prevalence, higher need for RRT and lower mortality. More studies are warranted to better understand AKI in hispanic COVID-19 patients as well as its distinct characteristics compared to the rest of the world.